This is a preview of subscription content, log in via an institution to check access.
Notes
2014 US dollars
Reference
Whittington MD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of Allergy, Asthma and Immunology : 3 Dec 2016. Available from: URL: http://doi.org/10.1016/j.anai.2016.10.028
Rights and permissions
About this article
Cite this article
Mepolizumab not cost effective for severe eosinophilic asthma. PharmacoEcon Outcomes News 769, 18 (2017). https://doi.org/10.1007/s40274-017-3654-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3654-z